Portolano Cavallo

Life Sciences

Blog

22 Nov
Medical research: Prior consultation with the Data Protection Authority is no longer required
Medical research is one of the areas most affected by rapid technological development and increased use of artificial intelligence (AI) systems.
21 Nov
Certifying digital procurement platforms (PADs)
Digital procurement platforms (“PADs”) are infrastructures used by contracting authorities for digital management of procurement in accordance with the provisions of the Public Procurement Code. They are necessary for digital execution of the entire lifecycle of public contracts and are an integral part of the Italian digital procurement ecosystem (e-procurement).
21 Nov
New AIFA guidelines on observational studies and decentralized clinical trials: Digital tools increasingly in focus
The AIFA issued two new guidelines, focusing, respectively, on observational studies and clinical trials for medicinal products.
21 Nov
New AIFA guidelines on simplification and decentralization of clinical trials
The AIFA approved guidelines concerning simplification and decentralization of clinical trials of medicines, on the same day as those on observational studies.
21 Nov
Transparency in clinical trials: Revised transparency rules take effect
The major changes under the revised transparency rules for the Clinical Trials Regulation and its Clinical Trials Information System, issued by the EMA in October 2023, should lead to faster publication of key documents (including protocols) and should make the system easier to use.
21 Nov
The Dabus case: Artificial intelligence cannot be designated as the inventor in a patent
Artificial intelligence plays a fundamental role in the life sciences sector, offering the opportunity to facilitate various processes. However, such use also raises numerous ethical and legal questions that touch on responsibility, reliability, and the correct and legal use of data and information to train AI for new technical solutions.
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the Life Sciences-Healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and Venture Capital transactions.

Close
October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Search
Follow us on
Follow us on